Melbourne Uni's 'nano-beacon' plays tricks with DNA
05 August, 2005 by Graeme O'NeillIn medicine, good things are coming in increasingly tiny packages: microscopic delivery systems made from polymers or other bio-friendly materials, and stuffed with therapeutic genes, proteins or small synthetic molecules, that can be implanted strategically in the brain or body.
Dispute between HeartWare and Ventracor heats up
04 August, 2005 by Helen SchullerThe legal battle between artificial heart firms HeartWare (ASX:HTW) and Ventracor (ASX:VCR) has intensified, with HeartWare filing a strong rebuttal to patent infringement action commenced against it by Ventracor and the University of Technology, Sydney.
Biotech to get Club fever
04 August, 2005 by Iain ScottJust what is the centre of the Australian biotech universe? Is it Melbourne, or Sydney, or Brisbane?
Genesis Biomedical reveals details of $1m rights issue
04 August, 2005 by Ruth BeranGenesis Biomedical (ASX:GBL) will be undertaking a non-renounceable rights issue to raise about AUD$1 million.
Circadian clocks up $21.8m profit
03 August, 2005 by Ruth BeranVeteran biotech investment group Circadian Technologies (ASX:CIR) has posted an AUD$21.77 million profit before tax for the 2004/05 financial year, up from $5.8 million for the previous corresponding year.
Norwood Immunology, US hospital team up for tolerance trial
03 August, 2005 by Ruth BeranMelbourne immune therapy developer Norwood Immunology (AIM:NIM) has signed a collaboration agreement with the Massachusetts General Hospital in Boston to conduct a proof-of-concept preclinical trial to determine whether tolerance to donated organ transplants can be established without the need for prolonged immunosuppressants.
LCT elated by Huntington's preclinical study
02 August, 2005 by Graeme O'NeillAuckland-based Living Cell Therapies (ASX:LCT) today announced "extraordinary" results from its preclinical trial of alginate-encapsulated pig brain cells in a primate model of Huntington's disease.
BresaGen signs two new contracts
02 August, 2005 by Helen SchullerAdelaide-based BresaGen (ASX:BGN) has signed two new contracts under its protEcol Services business unit.
Solbec falls foul of continuous disclosure laws
02 August, 2005 by Ruth BeranPerth-based Solbec Pharmaceuticals (ASX:SBP) has paid a AUD$33,000 fine after being issued with an infringement notice by the Australian Securities and Investments Commission (ASIC) for allegedly failing to disclose information to the Australian Stock Exchange (ASX) relating to a drug trial.
Cytopia trials given FDA OK
01 August, 2005 by Graeme O'NeillThe US Food and Drug Administration has approved a clinical trial of Melbourne biopharma Cytopia's (ASX:CYT) promising dual-acting lead anti-cancer molecule CYT997.
First Sunshine Heart device implant recipient dies
29 July, 2005 by Ruth BeranThe first patient to receive Sunshine Heart's (ASX:SHC) C-Pulse heart assist device on May 4, has died from multi-organ failure, 11.5 weeks after the implant.
NASDAQ launches new Health Care Index
29 July, 2005 by Ruth BeranThe NASDAQ stock market has launched a new Health Care Index (NASDAQ:IXHC), a market-value weighted index that contains NASDAQ listed companies classified as health, pharmaceutical or biotechnology.
Rockeby biomed raises $1 million
29 July, 2005 by Ruth BeranSingapore's Rockeby biomed (ASX:RBY) has raised just over AUD$1 million in a non-renounceable one-for-one share rights issue to shareholders, approximately $786,000 less than the AUD$1.78 million it hoped for.
ChemGenex receives two ARC linkage grants
28 July, 2005 by Ruth BeranMelbourne and California-based ChemGenex Pharmaceuticals (ASX:CXS) has been awarded two linkage project grants worth AUD$525,000 in cash from the Australian Research Council (ARC) over the next three years.
EQiTX increases equity in ZingoTX
28 July, 2005 by Ruth BeranMelbourne-based biotech managed investment group EQiTX (ASX:EQX) has increased its ownership in pain management company ZingoTX to 54 per cent with an equity instalment of AUD$300,000, bringing its total investment in ZingoTX to $1.9 million.
